Haemonetics Wins Back CSL — and Pays the Bill Up Front
Revenue guidance went up, margin-expansion guidance got cut in half, and the stock is already up 66% in three months. Investors are buying fiscal 2028, not this year's P&L.
HAE · Earnings Call · 2026-11-05
A raise with a hole in it
On the surface, Haemonetics' fiscal Q2 2027 was a clean beat-and-raise: organic revenue growth of 10%, adjusted EPS of $1.35 (+6%), adjusted gross margin of 61.9%, up about 140 basis points. Guidance went up — organic growth to 6%-9% from 4%-7%, reported to 8%-11% from 5%-8%. Then the other hand: full-year adjusted operating margin expansion was cut to 0-50 basis points from 50-100.
That asymmetry is the whole report. The company is pre-building manufacturing, warehousing, device inventory and expedited freight for a customer that has not yet shipped volume, and it is paying for it now. CFO James D'Arecca was unusually explicit that some of the pain is already capitalized: elevated production costs sit in inventory and “flow through COGS in the second half as product is sold. Gross margin will carry part of the pressure, not just operating expenses.” — James D'Arecca, Chief Financial Officer · 2026-11-05
Three things drove the margin reset, and the company's own keyword machinery flagged all of them. performance based compensation ranks first in Haemonetics' keyword set this quarter — the single biggest swing factor, sized at roughly 60/40 against elevated production costs, because the CSL contract itself is contributing to this year's outperformance against plan. Second, transitory costs, a phrase that appears nowhere in prior calls and now does a lot of work. Third, the tariff refund benefit that flattered the quarter: about 200 basis points of gross margin, partly offset by a 60bp FX headwind.
That last one is this reporting season's loudest cross-sector theme — tariff refunds also showed up in the same week at Henry Schein, JELD-WEN, Keurig Dr Pepper, Rockwell and Teleflex. Strip it out and Haemonetics' gross margin was essentially flat year over year. The quality-of-earnings question writes itself.
The catalyst nobody would size
Here is what actually changed. In August, Chris Simon was asked whether CSL was fully out of the business and whether the win-back was in the guide: “we don't have a signed contract and a committed time line, we're going to hold off on putting that in. That's just discipline in our go-forward guidance.” — Christopher Simon, Chief Executive Officer (CEO) · 2026-08-06 Three months later, it is signed. CSL takes the full Persona PLUS suite plus updated software, pilot conversions ran in September, full-scale conversion began in October, and all of CSL's U.S. plasma centers are scheduled to be converted before the end of calendar 2027.
And yet, asked three separate times to size it — by Baird, BTIG and JPMorgan — management gave the same answer:
We really appreciate and understand the push for quantification and clarity of timing. However, for confidentiality and competitive reasons, we cannot disclose customer-specific economics and plans.
So the biggest catalyst in the equity story is entirely unquantified, and management leaned on competitive reasons to say so — a keyword that didn't exist in this company's vocabulary a quarter ago. What we can infer: the CSL rollout adds roughly 50% more plasma volume over time, per Simon, and James D'Arecca pushed the P&L contribution to "fiscal 2028 and beyond." In the quarter just reported, CSL was "minimal, de minimis" — which means plasma's 18% organic growth was pure market and share capture.
What management stopped saying
The most revealing signal is in the keywords that fell. Commercial execution was a top-five gainer last quarter; this quarter it is among the sharpest decliners. return to growth — the framing that carried four straight calls for Interventional Technologies — collapsed too.
Worth remembering: in February, Simon declared “Fourth quarter of fiscal '26 is when Haemonetics IVT turned the corner.” — Christopher Simon, Chief Executive Officer · 2026-05-08 Two quarters later, IVT grew 3% organically in Q2, the same as Q1, against an access-site market the company itself sizes at 6%-7%. The new language is defensive and honest: “I believe we've laid the groundwork for success. We now need to live into that success.” — Chris Simon, Chief Executive Officer · 2026-11-05
The replacement narrative is product launches — PerQseal Elite, the FDA-approved large-bore closure device aimed at a $300 million TAVR/EVAR market, and PacePro for structural heart — both explicitly excluded from FY27 revenue and both framed as long-runway, not near-term. MedSurg organic growth of 6% came with a reaffirmed mid-single-digit guide, not a raised one. Every dollar of the guidance increase came from apheresis.
The quiet de-risking sits in Blood Management: the TEG 5000 capital upgrade cycle is winding down, but the business is now 85% disposables and TEG 6s recurring revenue is growing mid-teens, while transfusion management has reached roughly 20% of BMT revenue at high-teens growth. That is a capital-cycle cliff converted into an annuity.
The productivity paradox
Plasma is where the real intellectual tension lives. Persona PLUS now carries the majority of U.S. collection volume, delivering 5%-6% incremental yield per collection. That is precisely why collectors can afford to collect less. Simon did not dodge it: “Some of our collectors, yes, will take that as an opportunity in the near term to back off.” — Chris Simon, Chief Executive Officer · 2026-11-05 It happened before — “some of the largest collectors took the 10% yield and met their annual objectives, and we're able to meaningfully lower cost per liter as a result.” — Christopher Simon, Chief Executive Officer · 2026-05-08
Which is why collection volume growth has been excluded from guidance for five consecutive quarters. That is discipline, not evasion — and it means the high-single-digit apheresis guide leans almost entirely on share and confirmed CSL conversions through the December quarter.
The tape has already voted on this cluster. Globally, the cost per liter theme baskets Grifols, Haemonetics and CSL — up roughly 41% over 90 days. Grifols reported this week citing a "phased resumption of plasma collections," corroborating the end-market recovery from the customer side rather than the equipment side.
The price of being early
Haemonetics' stock has risen 65.8% in the last 90 days in one uninterrupted trend segment, leaving it about 11% below its February 2021 peak of $139.48. Oddly, the valuation has not run away on cash: price to free cash flow sits at 13.2x, down 42% year over year, because free cash flow (less SBC) hit $35 million, up 711% year over year, with first-half operating cash flow up 40% to $180 million.
That is what makes the setup interesting rather than merely expensive. The company has roughly $951 million of effective net debt, $261 million of cash, about 2.5x credit-agreement leverage and $325 million of unused buyback authorization. It guided free cash flow conversion down to "in excess of 80%" of adjusted net income from 111% trailing, explicitly to fund inventory, CapEx and device placements.
The bull case is fiscal 2028: transitory costs roll off, a production base expanded by more than 40% gets absorbed, fixed costs spread across 50% more plasma volume, and a "high 20s" operating margin aspiration comes back into view. The bear case is that second-half margin expansion is back-end weighted to Q4, CSL economics stay undisclosed until confirmations arrive, and a stock that has already doubled gets no benefit of the doubt if the fourth quarter slips. Management got the win. Now it has to earn the multiple it has already been given.